Toggle Offcanvas
...
 
Dolutegravir Tenders

Dolutegravir Tenders

View Dolutegravir tenders, RFPs and contracts. Bid on readily available Dolutegravir tenders with the best and most comprehensive tendering platform, since 2002.
Dolutegravir is an antiretroviral drug used in the treatment of HIV/AIDS, often combined with other medications. It blocks the HIV enzyme integrase, preventing the virus from replicating and lowering the viral load in the body.

Bidding for Dolutegravir tenders is extremely lucrative for companies of all sizes. Tendering authorities and private companies release thousands of contracts worth millions for procurement of Dolutegravir.

Global Tenders stands out as the largest platform dedicated to pharmaceutical tenders and government contracts. Boasting over 20 years of experience in the tender business, GlobalTenders offers the most extensive and reliable Tenders/RFPs/Contracts Database available. The platform aggregates contracts from both public and private sources, connecting with a vast network of over half a million buyers. Employing advanced artificial intelligence, our meticulous process involves gathering information from over a hundred thousand sources. The data is then intelligently categorized into thousands of subcategories for easy filtering and presenting it in a user-friendly format for quick comprehension.

In addition to tender information, we offer in-depth Dolutegravir market analysis, bid consultancy services, and insights into top bidders and winners.

Sign up now to get instant access to unlimited Dolutegravir tenders, advanced search filters, market analysis, industry trends, tender training and 24/7 customer support.

35 Live Notices for Dolutegravir Tenders

Showing 1 to 20

Req. 25-455 Dolutegravir 50 Mg, Covered Tablet, V.O. F.T. 105700.
country Panama
posting date14 Mar 2025
deadline29 Mar 2025
Req. 25-455 Dolutegravir 50 Mg, Covered Tablet, V.O. F.T. 105700.
country Panama
posting date14 Mar 2025
deadline29 Mar 2025
Open House Contracts 2025-1
country Germany
posting date11 Mar 2025
deadline02 May 2025
Open House Contracts 2025-1
country Germany
posting date11 Mar 2025
deadline02 May 2025
Open House Original Discount Agreements 2025-06 - Dolutegravir
country Germany
posting date22 Jan 2025
deadline28 Feb 2027
Open House Original Discount Agreements 2025-06 - Dolutegravir
country Germany
posting date22 Jan 2025
deadline28 Feb 2027
Open House Original Discount Agreements 2025-07 - Lamivudine/Abacavir/Dolutegravir (Active Ingredient Combination)
country Germany
posting date22 Jan 2025
deadline28 Feb 2027
Open House Original Discount Agreements 2025-07 - Lamivudine/Abacavir/Dolutegravir (Active Ingredient Combination)
country Germany
posting date22 Jan 2025
deadline28 Feb 2027
Open House Original Discount Agreements 2025-07 - Lamivudine/Abacavir/Dolutegravir (Active Ingredient Combination)
country Germany
posting date22 Jan 2025
deadline28 Feb 2027
Open House Original Discount Agreements 2025-07 - Lamivudine/Abacavir/Dolutegravir (Active Ingredient Combination)
country Germany
posting date22 Jan 2025
deadline28 Feb 2027
Open House Original Discount Agreements 2025-06 - Dolutegravir
country Germany
posting date22 Jan 2025
deadline28 Feb 2027
Open House Original Discount Agreements 2025-06 - Dolutegravir
country Germany
posting date22 Jan 2025
deadline28 Feb 2027
Conclusion Of Non-Exclusive Discount Agreements Pursuant To Section 130A Paragraph 8/130C Paragraph 1 Sgb V For Medicinal Products Containing The Active Ingredients Dolutegravir And Rilpivirine (J05Ar21) Within The Framework Of A So-Called Open-House Model.
country Germany
posting date14 Jun 2024
deadline31 May 2026
Conclusion Of Non-Exclusive Discount Agreements Pursuant To Section 130A Paragraph 8/130C Paragraph 1 Sgb V For Medicinal Products Containing The Active Ingredients Dolutegravir And Rilpivirine (J05Ar21) Within The Framework Of A So-Called Open-House Model.
country Germany
posting date14 Jun 2024
deadline31 May 2026
Conclusion Of Non-Exclusive Discount Agreements Pursuant To Section 130A Paragraph 8/130C Paragraph 1 Sgb V For Medicinal Products Containing The Active Ingredients Dolutegravir And Rilpivirine (J05Ar21) Within The Framework Of A So-Called Open-House Model.
country Germany
posting date12 Jun 2024
deadline31 May 2026
Conclusion Of Non-Exclusive Discount Agreements Pursuant To Section 130A Paragraph 8/130C Paragraph 1 Sgb V For Medicinal Products Containing The Active Ingredients Dolutegravir And Rilpivirine (J05Ar21) Within The Framework Of A So-Called Open-House Model.
country Germany
posting date12 Jun 2024
deadline31 May 2026
Open House Contracts For Several Active Ingredients/Combinations Of Active Ingredients
country Germany
posting date14 May 2024
deadline04 May 2026
Open House Contracts For Several Active Ingredients/Combinations Of Active Ingredients
country Germany
posting date14 May 2024
deadline04 May 2026
Open House Original Discount Agreements 2023-32 - Dolutegravir/Rilpivirine (Combination Of Active Ingredients)
country Germany
posting date15 Sep 2023
deadline31 Oct 2025
Open House Original Discount Agreements 2023-32 - Dolutegravir/Rilpivirine (Combination Of Active Ingredients)
country Germany
posting date15 Sep 2023
deadline31 Oct 2025

Share Share this page